Reimbursement Tops List Of Venture Capital Concern Over Device Start-Ups
This article was originally published in The Gray Sheet
Executive Summary
The low number of first-round venture capital (VC) deals in 1999 among medical device start-ups is cause for concern, according Casey McGlynn, of the Silicon Valleuy law firm Wilson Sonsini Goodrich & Rosati.
You may also be interested in...
Drug Pricing Scrutiny Could Impact Device Stocks - Merrill Lynch Analyst
Stock valuations in the medical device sector may be adversely affected by the threat of federal scrutiny over U.S. prescription drug pricing, given the tendency of some investors to lump devices with drugs when making decisions, according to Merrill Lynch medical device analyst Daniel Lemaitre.
Drug Pricing Scrutiny Could Impact Device Stocks - Merrill Lynch Analyst
Stock valuations in the medical device sector may be adversely affected by the threat of federal scrutiny over U.S. prescription drug pricing, given the tendency of some investors to lump devices with drugs when making decisions, according to Merrill Lynch medical device analyst Daniel Lemaitre.
Innovation Not Forgotten Art For Device Conglomerates - Wharton Panel
Large device companies play a significant role in medical technology innovation, contrary to the somewhat widespread belief that the start-up sector is the primary driver of R&D, Boston Scientific Chairman Peter Nicholas maintained.